On the public citation graph

A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development

https://doi.org/10.3390/pathogens10070788
0 signed · 121 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2020.15543openalex-snapshot
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes
inferredcites →https://doi.org/10.1001/jama.2021.2927openalex-snapshot
The Johnson & Johnson Vaccine for COVID-19
inferredcites →https://doi.org/10.1016/j.addr.2021.01.001openalex-snapshot
Recombinant protein vaccines, a proven approach against coronavirus pandemics
inferredcites →https://doi.org/10.1016/j.ajog.2021.03.023openalex-snapshot
Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study
inferredcites →https://doi.org/10.1016/j.cell.2020.06.035openalex-snapshot
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS
inferredcites →https://doi.org/10.1016/j.nmni.2020.100786openalex-snapshot
Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach
inferredcites →https://doi.org/10.1016/j.str.2020.10.001openalex-snapshot
The Architecture of Inactivated SARS-CoV-2 with Postfusion Spikes Revealed by Cryo-EM and Cryo-ET
inferredcites →https://doi.org/10.1016/j.vaccine.2021.01.055openalex-snapshot
Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data
inferredcites →https://doi.org/10.1016/s0140-6736(20)31208-3openalex-snapshot
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
inferredcites →https://doi.org/10.1016/s0140-6736(20)31252-6openalex-snapshot
COVID-19 vaccine development pipeline gears up
inferredcites →https://doi.org/10.1016/s0140-6736(20)31605-6openalex-snapshot
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
inferredcites →https://doi.org/10.1016/s0140-6736(20)32156-5openalex-snapshot
Use of adenovirus type-5 vectored vaccines: a cautionary tale
inferredcites →https://doi.org/10.1016/s0140-6736(20)32623-4openalex-snapshot
Oxford–AstraZeneca COVID-19 vaccine efficacy
inferredcites →https://doi.org/10.1016/s0140-6736(20)32661-1openalex-snapshot
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
inferredcites →https://doi.org/10.1016/s0140-6736(21)00191-4openalex-snapshot
Sputnik V COVID-19 vaccine candidate appears safe and effective
inferredcites →https://doi.org/10.1016/s0140-6736(21)00234-8openalex-snapshot
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
inferredcites →https://doi.org/10.1016/s0140-6736(21)00448-7openalex-snapshot
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
inferredcites →https://doi.org/10.1016/s1473-3099(20)30843-4openalex-snapshot
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
inferredcites →https://doi.org/10.1016/s1473-3099(20)30942-7openalex-snapshot
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
inferredcites →https://doi.org/10.1016/s1473-3099(21)00070-0openalex-snapshot
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
inferredcites →https://doi.org/10.1016/s1473-3099(21)00094-3openalex-snapshot
Adjuvantation helps to optimise COVID-19 vaccine candidate
inferredcites →https://doi.org/10.1038/d41586-021-00998-wopenalex-snapshot
COVID vaccines and blood clots: five key questions
inferredcites →https://doi.org/10.1038/s41418-020-00720-9openalex-snapshot
COVID-19 vaccines: where we stand and challenges ahead
inferredcites →https://doi.org/10.1038/s41467-020-16505-0openalex-snapshot
Immunogenicity of a DNA vaccine candidate for COVID-19
inferredcites →https://doi.org/10.1038/s41467-020-17409-9openalex-snapshot
Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
inferredcites →https://doi.org/10.1038/s41467-020-20654-7openalex-snapshot
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
inferredcites →https://doi.org/10.1038/s41467-021-21665-8openalex-snapshot
Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques
inferredcites →https://doi.org/10.1038/s41541-021-00292-wopenalex-snapshot
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
inferredcites →https://doi.org/10.1038/s41565-020-0732-3openalex-snapshot
Immune-mediated approaches against COVID-19
inferredcites →https://doi.org/10.1038/s41577-020-00480-0openalex-snapshot
Viral targets for vaccines against COVID-19
inferredcites →https://doi.org/10.1038/s41586-021-03398-2openalex-snapshot
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
inferredcites →https://doi.org/10.1038/s41586-021-03530-2openalex-snapshot
Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
inferredcites →https://doi.org/10.1038/s41590-020-00808-xopenalex-snapshot
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition
inferredcites →https://doi.org/10.1038/s41590-020-0782-6openalex-snapshot
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
inferredcites →https://doi.org/10.1056/nejmoa2026920openalex-snapshot
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
inferredcites →https://doi.org/10.1056/nejmoa2034577openalex-snapshot
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
inferredcites →https://doi.org/10.1056/nejmoa2035389openalex-snapshot
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
inferredcites →https://doi.org/10.1073/pnas.2026207118openalex-snapshot
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
inferredcites →https://doi.org/10.1073/pnas.2026785118openalex-snapshot
One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection
inferredcites →https://doi.org/10.1074/jbc.ra120.016148openalex-snapshot
SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like particles
inferredcites →https://doi.org/10.1101/2020.09.09.285445openalex-snapshot
Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152
inferredcites →https://doi.org/10.1101/2020.12.30.424878openalex-snapshot
MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease
inferredcites →https://doi.org/10.1126/sciadv.abe8065openalex-snapshot
Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans
inferredcites →https://doi.org/10.1126/science.370.6517.649openalex-snapshot
The long shot
inferredcites →https://doi.org/10.1126/science.abg8101openalex-snapshot
Novavax vaccine delivers 89% efficacy against COVID-19 in U.K.—but is less potent in South Africa
inferredcites →https://doi.org/10.1136/bmj.n359openalex-snapshot
Covid-19: The E484K mutation and the risks it poses
inferredcites →https://doi.org/10.1136/bmj.n997openalex-snapshot
What do we know about India’s Covaxin vaccine?
inferredcites →https://doi.org/10.1159/000509368openalex-snapshot
Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association with COVID-19 Vaccination and Infection
inferredcites →https://doi.org/10.1186/s12929-020-00695-2openalex-snapshot
Coronavirus vaccine development: from SARS and MERS to COVID-19
inferredcites →https://doi.org/10.1186/s43556-020-00015-yopenalex-snapshot
Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19
inferredcites →https://doi.org/10.12659/msm.924700openalex-snapshot
An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
inferredcites →https://doi.org/10.13140/rg.2.2.11136.46086openalex-snapshot
COVID-19 Vaccine: An Update and Primer
inferredcites →https://doi.org/10.15537/1658-3175.7683openalex-snapshot
WHO ISSUES ITS FIRST EMERGENCY USE VALIDATION FOR A COVID-19 VACCINE AND EMPHASIZES NEED FOR EQUITABLE GLOBAL ACCESS
inferredcites →https://doi.org/10.3346/jkms.2021.36.e54openalex-snapshot
What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021
inferredcites →https://doi.org/10.3390/pharmaceutics13010045openalex-snapshot
Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines
inferredcites →https://doi.org/10.3390/v12111324openalex-snapshot
Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19
inferredcites →https://doi.org/10.3390/v13010005openalex-snapshot
Plant-Based Vaccines: The Way Ahead?
inferredcites →https://doi.org/10.3390/vaccines8040649openalex-snapshot
COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response
inferredcites →https://doi.org/10.37871/ajeph.id39openalex-snapshot
COVID-19 Vaccines-Safety First, Alleged “Greater Good” Last
inferredcites →https://doi.org/10.4110/in.2021.21.e4openalex-snapshot
Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4678559openalex-extracted
Responsible Innovation for Disruptive Science and Technology: Modelling the Pathways for Building Public Trust and Expectations of Socially Responsible Outcomes
inferred← citeshttps://doi.org/10.1002/btpr.3292openalex-snapshot
Development of virus‐like particles‐based vaccines against coronaviruses
inferred← citeshttps://doi.org/10.1002/mco2.158openalex-snapshot
Outbreak control management: Lessons from SARS‐CoV‐2 infections in 2020–2022 in Hong Kong, an international municipality with high‐frequency travelers
inferred← citeshttps://doi.org/10.1002/slct.202103301openalex-snapshot
An Update on Pharmacological Relevance and Chemical Synthesis of Natural Products and Derivatives with Anti SARS‐CoV‐2 Activity
inferred← citeshttps://doi.org/10.1007/978-3-031-94270-9_7openalex-snapshot
Coronavirus Disease (COVID-19)
inferred← citeshttps://doi.org/10.1007/978-981-19-9936-9_18openalex-snapshot
The Potential Role of Medicinal Plants, Traditional Herbal Medicines, and Formulations to Overcome SARS-CoV-2 Induced Health Crisis
inferred← citeshttps://doi.org/10.1007/s00449-022-02788-8openalex-snapshot
Understanding and combating COVID-19 using the biology and chemistry of SARS-CoV-2
inferred← citeshttps://doi.org/10.1007/s12275-022-1621-2openalex-snapshot
COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity
inferred← citeshttps://doi.org/10.1007/s13337-022-00755-1openalex-snapshot
A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges
inferred← citeshttps://doi.org/10.1016/j.hsr.2023.100127openalex-snapshot
Virus-like particles (VLPs)-based vaccines against COVID-19: Where do we stand amid the ongoing evolution of SARS-CoV-2?
inferred← citeshttps://doi.org/10.1016/j.intimp.2022.109650openalex-snapshot
A perspective on SARS-CoV-2 virus-like particles vaccines
inferred← citeshttps://doi.org/10.1016/j.iref.2024.02.055openalex-snapshot
A sustainable pandemic response: The impact of COVID-19 vaccination coverage on economic policy uncertainty
inferred← citeshttps://doi.org/10.1016/j.jiph.2022.10.006openalex-snapshot
A systematic review of current status and challenges of vaccinating children against SARS-CoV-2
inferred← citeshttps://doi.org/10.1016/j.techsoc.2024.102709openalex-snapshot
Responsible innovation for disruptive science and technology: The role of public trust and social expectations
inferred← citeshttps://doi.org/10.1016/j.vaccine.2021.11.052openalex-snapshot
A retrospective analysis of social media posts pertaining to COVID-19 vaccination side effects
inferred← citeshttps://doi.org/10.1038/s41541-023-00636-8openalex-snapshot
PF-D-Trimer, a protective SARS-CoV-2 subunit vaccine: immunogenicity and application
inferred← citeshttps://doi.org/10.1063/5.0119810openalex-snapshot
A proposed IoNT-based system to monitoring the validity of Covid-19 vaccine
inferred← citeshttps://doi.org/10.1080/14760584.2022.2021074openalex-snapshot
The race for a COVID-19 vaccine: where are we up to?
inferred← citeshttps://doi.org/10.1080/21645515.2023.2217076openalex-snapshot
Sweet syndrome induced by SARS-CoV-2 vaccines: A systematic review of patient-report studies
inferred← citeshttps://doi.org/10.1101/2021.08.24.21262239openalex-snapshot
Recent COVID-19 vaccination is associated with modest increases in the physiological demands to graded exercise
inferred← citeshttps://doi.org/10.1126/sciadv.abn4188openalex-snapshot
Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities
inferred← citeshttps://doi.org/10.1152/japplphysiol.00629.2021openalex-snapshot
Recent COVID-19 vaccination has minimal effects on the physiological responses to graded exercise in physically active healthy people
inferred← citeshttps://doi.org/10.1155/2022/6913772openalex-snapshot
Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines
inferred← citeshttps://doi.org/10.1186/s11658-022-00339-3openalex-snapshot
An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)
inferred← citeshttps://doi.org/10.1186/s12879-023-08754-3openalex-snapshot
Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis
inferred← citeshttps://doi.org/10.1371/journal.pone.0263468openalex-snapshot
Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection—A comparative study from Novi Sad, Serbia
inferred← citeshttps://doi.org/10.14302/issn.2691-8862.jvat-21-3999openalex-snapshot
Characterization of the Vaccine Abdala
inferred← citeshttps://doi.org/10.14814/phy2.15556openalex-snapshot
The COVID ‐19 vaccine did not affect the basal immune response and menstruation in female athletes
inferred← citeshttps://doi.org/10.2147/aabc.s366111openalex-snapshot
In silico Drug Repurposing of Anticancer Drug 5-FU and Analogues Against SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics Simulation, Pharmacokinetics and Chemical Reactivity Studies
inferred← citeshttps://doi.org/10.2147/idr.s332354openalex-snapshot
Adverse Effects of the COVID-19 Vaccine Reported by Lecturers and Staff of Kabul University of Medical Sciences, Kabul, Afghanistan
inferred← citeshttps://doi.org/10.23880/vvoa-16000160openalex-snapshot
Different Potential Vaccine Candidates of Covid-19 Diseases and their Immunological Aspect
inferred← citeshttps://doi.org/10.26434/chemrxiv-2021-gk1gtopenalex-snapshot
In silico drug repurposing of anticancer drug 5-FU and analogues against SARS-CoV-2 main protease
inferred← citeshttps://doi.org/10.29196/jubpas.v30i1.4071openalex-snapshot
Covid-19 Vaccines in Iraq
inferred← citeshttps://doi.org/10.31631/2073-3046-2022-21-4-113-118openalex-snapshot
Analyzing the Problem of Mass Rejection of Vaccination against COVID-19. Possible Solutions
inferred← citeshttps://doi.org/10.31631/2073-3046-2023-22-1-82-88openalex-snapshot
Frequency of SARS-CoV-2 RNA Detection in Foreign Medical Students Vaccined against New Coronavirus Infection
inferred← citeshttps://doi.org/10.33425/2690-537x.1023openalex-snapshot
Moderna Arm Cutaneous Side Effect of Moderna Vaccine among Healthcare Providers in Secondary Hospital in Jakarta - Tangerang, Indonesia.
inferred← citeshttps://doi.org/10.3389/fmicb.2021.752739openalex-snapshot
An Intranasal Vaccine Based on Outer Membrane Vesicles Against SARS-CoV-2
inferred← citeshttps://doi.org/10.3389/fmicb.2022.828984openalex-snapshot
Identification of Hypericin as a Candidate Repurposed Therapeutic Agent for COVID-19 and Its Potential Anti-SARS-CoV-2 Activity
inferred← citeshttps://doi.org/10.3389/fmicb.2022.927306openalex-snapshot
A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19
inferred← citeshttps://doi.org/10.3389/fnano.2022.948705openalex-snapshot
Application of Nanoparticles in Tumour Targeted Drug Delivery and Vaccine
inferred← citeshttps://doi.org/10.3390/antiox10111794openalex-snapshot
Antioxidant Activity of Citrus Limonoids and Investigation of Their Virucidal Potential against SARS-CoV-2 in Cellular Models
inferred← citeshttps://doi.org/10.3390/ijerph18179210openalex-snapshot
To Vaccinate or Not to Vaccinate—This Is the Question among Swiss University Students
inferred← citeshttps://doi.org/10.3390/pathogens12020329openalex-snapshot
The Role of Immunity in the Pathogenesis of SARS-CoV-2 Infection and in the Protection Generated by COVID-19 Vaccines in Different Age Groups
inferred← citeshttps://doi.org/10.3390/pathogens12101253openalex-snapshot
A Brief Focus on SARS-CoV-2 Genomic Evolution and Vaccines
inferred← citeshttps://doi.org/10.3390/ph14080736openalex-snapshot
Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review
inferred← citeshttps://doi.org/10.3390/ph14080762openalex-snapshot
Prevalence and Significance of Hypermetabolic Lymph Nodes Detected by 2-[18F]FDG PET/CT after COVID-19 Vaccination: A Systematic Review and a Meta-Analysis
inferred← citeshttps://doi.org/10.3390/vaccines10101676openalex-snapshot
Sports Elite Means Vaccine Elite? Concerns and Beliefs Related to COVID-19 Vaccines among Olympians and Elite Athletes
inferred← citeshttps://doi.org/10.3390/vaccines10101706openalex-snapshot
Maintenance of Antibody Response in Egyptian Healthcare Workers Vaccinated with ChAdOx1 nCoV-19 Vaccine during Delta and Omicron Variants Pandemic: A Prospective Study
inferred← citeshttps://doi.org/10.3390/vaccines9080889openalex-snapshot
Mandate or Not Mandate: Knowledge, Attitudes, and Practices of Italian Occupational Physicians towards SARS-CoV-2 Immunization at the Beginning of Vaccination Campaign
inferred← citeshttps://doi.org/10.3390/vaccines9111345openalex-snapshot
The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview
inferred← citeshttps://doi.org/10.3390/vaccines9121492openalex-snapshot
A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses
inferred← citeshttps://doi.org/10.34108/eujhs.989664openalex-snapshot
COVID-19 AŞISINDA GÜNCEL UYGULAMALAR
inferred← citeshttps://doi.org/10.3855/jidc.17691openalex-snapshot
Side effects of COVID-19 vaccines among Iranian healthcare workers: a retrospective cohort study
inferred← citeshttps://doi.org/10.4018/ijqspr.2021100101openalex-snapshot
Perspectives for Potential Therapies for SARS-CoV-2
inferred← citeshttps://doi.org/10.47941/jep.2645openalex-snapshot
Students’ Perception of Teaching and Learning During Pandemics: A Case Study
inferred← citeshttps://doi.org/10.53350/pjmhs22163429openalex-snapshot
Frequency and Pattern of Myths and Misconception regarding Covid- 19 Vaccine in General Population
inferred← citeshttps://doi.org/10.58837/chula.the.2022.287openalex-snapshot
Stimulation of immune response in mice using the plant-produced SARS-CoV-2 S1 subunit protein linked to the fc region
inferred← citeshttps://doi.org/10.6084/m9.figshare.25264278openalex-snapshot
Additional file 1 of Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis
inferred← citeshttps://doi.org/10.6084/m9.figshare.25264439openalex-snapshot
Additional file 2 of Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis
inferred← citeshttps://doi.org/10.61091/jpms202413118openalex-snapshot
Elevated Serum Levels of SARS-CoV-2 Anti-Spike S1 RBD IgM, IgG, and IgA in Pfizer-BioNTech Vaccinated, COVID-19 Infected, and COVID-19 Infected after Pfizer-BioNTech Vaccinated Individuals after One Month
inferred← citeshttps://doi.org/10.7150/ijbs.68973openalex-snapshot
A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.